Literature DB >> 8120035

Disulfide bonds required to assemble functional von Willebrand factor multimers.

Z Dong1, R S Thoma, D L Crimmins, D W McCourt, E A Tuley, J E Sadler.   

Abstract

The hemostatic functions of human von Willebrand Factor (vWF) depend on the normal assembly of disulfide-linked multimers from approximately 250-kDa subunits. Subunits initially form dimers through disulfide bonds near the COOH terminus. Dimers then form multimers through disulfide bonds near the NH2 terminus of each subunit. Previous studies of plasma vWF and recombinant vWF fragments indicate that 1 or more of the Cys residues at position 459, 462, and 464 form intersubunit disulfide bonds. No evidence has been reported that vWF multimer formation involves additional intersubunit bonds. To probe the disulfide bond requirements for multimer formation, mutant vWF proteins were expressed in which all 3 Cys residues at positions 459, 462, and 464 were changed to either Gly or Ala. Surprisingly, none of these cysteines appears to be necessary for efficient multimer assembly. Furthermore, recombinant vWF with Gly or Ala at all three positions induces platelet aggregation in the presence of ristocetin and binds to platelet glycoprotein Ib, factor VIII, and collagen in a manner similar to wild-type recombinant vWF. These results suggest that other intersubunit disulfide bonds must exist. Direct evidence for such a bond was obtained by characterization of tryptic fragments of vWF. By Edman degradation, amino acid composition, and mass spectrometry, a disulfide bond was demonstrated between Cys379 residues of adjacent vWF subunits. Thus, intersubunit disulfide bonds involving Cys379 and 1 or more of the Cys residues at positions 459, 462, and 464 connect the NH2-terminal ends of the vWF subunits in a parallel orientation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8120035

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  12 in total

1.  Distinct roles of Ser-764 and Lys-773 at the N terminus of von Willebrand factor in complex assembly with coagulation factor VIII.

Authors:  Lydia Castro-Núñez; Esther Bloem; Mariëtte G Boon-Spijker; Carmen van der Zwaan; Maartje van den Biggelaar; Koen Mertens; Alexander B Meijer
Journal:  J Biol Chem       Date:  2012-11-20       Impact factor: 5.157

2.  Interactions of β tubulin isotypes with glutathione in differentiated neuroblastoma cells subject to oxidative stress.

Authors:  Jiayan Guo; Hong Seok Kim; Reto Asmis; Richard F Ludueña
Journal:  Cytoskeleton (Hoboken)       Date:  2018-05-14

3.  Roles of calreticulin and calnexin during mucin synthesis in LS180 and HT29/A1 human colonic adenocarcinoma cells.

Authors:  D J McCool; Y Okada; J F Forstner; G G Forstner
Journal:  Biochem J       Date:  1999-08-01       Impact factor: 3.857

4.  Novel mutations involving βI-, βIIA-, or βIVB-tubulin isotypes with functional resemblance to βIII-tubulin in breast cancer.

Authors:  Weiwei Wang; Hangxiao Zhang; Xumin Wang; Jordan Patterson; Philip Winter; Kathryn Graham; Sunita Ghosh; John C Lee; Christos D Katsetos; John R Mackey; Jack A Tuszynski; Gane Ka-Shu Wong; Richard F Ludueña
Journal:  Protoplasma       Date:  2016-12-09       Impact factor: 3.356

5.  Two Cys residues essential for von Willebrand factor multimer assembly in the Golgi.

Authors:  Angie R Purvis; Julia Gross; Luke T Dang; Ren-Huai Huang; Milan Kapadia; R Reid Townsend; J Evan Sadler
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-25       Impact factor: 11.205

6.  Disulfide exchange in multimerization of von Willebrand factor and gel-forming mucins.

Authors:  Xianchi Dong; Timothy A Springer
Journal:  Blood       Date:  2021-03-04       Impact factor: 22.113

Review 7.  COVID-19 Sepsis: Pathogenesis and Endothelial Molecular Mechanisms Based on "Two-Path Unifying Theory" of Hemostasis and Endotheliopathy-Associated Vascular Microthrombotic Disease, and Proposed Therapeutic Approach with Antimicrothrombotic Therapy.

Authors:  Jae C Chang
Journal:  Vasc Health Risk Manag       Date:  2021-06-01

Review 8.  Recombinant von Willebrand factor: potential therapeutic use.

Authors:  B E Fischer
Journal:  J Thromb Thrombolysis       Date:  1999-10       Impact factor: 5.221

9.  Control of von Willebrand factor multimer size by thrombospondin-1.

Authors:  L Xie; C N Chesterman; P J Hogg
Journal:  J Exp Med       Date:  2001-06-18       Impact factor: 14.307

10.  Structural mechanism of VWF D'D3 dimer formation.

Authors:  Zimei Shu; Jianwei Zeng; Li Xia; Haiyan Cai; Aiwu Zhou
Journal:  Cell Discov       Date:  2022-02-15       Impact factor: 10.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.